These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 23962003

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T, Takimoto A, Notsu Y, Yoshida H, Ito T, Nagatome H, Ohno M, Kobayashi Y, Yoshioka T, Inagaki K, Yagi S, Hoffman RM, Esaki N.
    Cancer Res; 2006 Mar 01; 66(5):2807-14. PubMed ID: 16510603
    [Abstract] [Full Text] [Related]

  • 23. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.
    Biochem Biophys Res Commun; 2004 Mar 19; 315(4):808-14. PubMed ID: 14985084
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y, Kamei N, Khafagy el-S, Miyamoto M, Takeda-Morishita M.
    Int J Pharm; 2016 Aug 20; 510(1):304-10. PubMed ID: 27343364
    [Abstract] [Full Text] [Related]

  • 26. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
    Chang CH, Rossi EA, Cardillo TM, Nordstrom DL, McBride WJ, Goldenberg DM.
    Bioconjug Chem; 2009 Oct 21; 20(10):1899-907. PubMed ID: 19736932
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.
    Regul Pept; 2012 Jan 10; 173(1-3):74-81. PubMed ID: 21985916
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).
    Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE.
    Pharm Res; 1998 Apr 10; 15(4):641-9. PubMed ID: 9587963
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
    Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S.
    Bioconjug Chem; 2007 Apr 10; 18(1):61-76. PubMed ID: 17226958
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
    Hu X, Olivier K, Polack E, Crossman M, Zokowski K, Gronke RS, Parker S, Li Z, Nestorov I, Baker DP, Clarke J, Subramanyam M.
    J Pharmacol Exp Ther; 2011 Sep 10; 338(3):984-96. PubMed ID: 21690216
    [Abstract] [Full Text] [Related]

  • 34. A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.
    Imada T, Moriya K, Uchiyama M, Inukai N, Hitotsuyanagi M, Masuda A, Suzuki T, Ayukawa S, Tagawa YI, Dohmae N, Kohara M, Yamamura M, Kiga D.
    ACS Synth Biol; 2018 Nov 16; 7(11):2537-2546. PubMed ID: 30277749
    [Abstract] [Full Text] [Related]

  • 35. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
    Boccia A, Virata C, Lindner D, English N, Pathan N, Brickelmaier M, Hu X, Gardner JL, Peng L, Wang X, Zhang X, Yang L, Perron K, Yco G, Kelly R, Gamez J, Scripps T, Bennett D, Joseph IB, Baker DP.
    J Interferon Cytokine Res; 2017 Jan 16; 37(1):20-31. PubMed ID: 27835061
    [Abstract] [Full Text] [Related]

  • 36. Long-Acting Human Growth Hormone Receptor Antagonists Produced in E. coli and Conjugated with Polyethylene Glycol.
    Wang Y, Langley RJ, Tamshen K, Jamieson SM, Lu M, Maynard HD, Perry JK.
    Bioconjug Chem; 2020 Jun 17; 31(6):1651-1660. PubMed ID: 32423203
    [Abstract] [Full Text] [Related]

  • 37. In vitro biological characterization of IFN-β-1a major glycoforms.
    Mastrangeli R, Rossi M, Mascia M, Palinsky W, Datola A, Terlizzese M, Bierau H.
    Glycobiology; 2015 Jan 17; 25(1):21-9. PubMed ID: 25117008
    [Abstract] [Full Text] [Related]

  • 38. Design, development and evaluation of PEGylated rhGH with preserving its bioactivity at highest level after modification.
    Karbasian M, Kouchakzadeh H, Anamaghi PN, Sefidbakht Y.
    Int J Pharm; 2019 Feb 25; 557():9-17. PubMed ID: 30576790
    [Abstract] [Full Text] [Related]

  • 39. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
    McKenna SD, Vergilis K, Arulanandam AR, Weiser WY, Nabioullin R, Tepper MA.
    J Interferon Cytokine Res; 2004 Feb 25; 24(2):119-29. PubMed ID: 14980076
    [Abstract] [Full Text] [Related]

  • 40. PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.
    Kieseier BC, Calabresi PA.
    CNS Drugs; 2012 Mar 01; 26(3):205-14. PubMed ID: 22201341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.